BACKGROUND: LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance. METHODS: First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promoter reporter constructs was determined in BeWo trophoblast-like cells with luciferase assays. Adjusted odds ratio (OR) was calculated for the A/A genotype combined with maternal risk factors. RESULTS: The A/A, A/C, and C/C genotypes in the -98 promoter position were in Hardy-Weinberg equilibrium in the control but not in the PE group (p < 0.036). The dominant A/A genotype had higher frequency in the PE group (p < 0.001). The A/C and C/C genotypes protected from PE (p < 0.032). The ORs to develop term and all PE, calculated for the A/A genotype, previous PE, body mass index (BMI) >35, black ethnicity, and maternal age >40 were 15.6 and 11.0, respectively (p < 0.001). In luciferase assays, the "-98A" promoter variant had lower expression than the "-98C" variant in non-differentiated (-13%, p = 0.04) and differentiated (-26%, p < 0.001) BeWo cells. Forskolin-induced differentiation led to a larger expression increase in the "-98C" variant than in the "-98A" variant (4.55-fold vs. 3.85-fold, p < 0.001). CONCLUSION: Lower LGALS13 (PP13) expression with the "A" nucleotide in the -98 promoter region position (compared to "C") and high OR calculated for the A/A genotype in the -98A/C promoter region position, history of previous PE, BMI >35, advanced maternal age >40, and black ethnicity could serve to aid in PE prediction in the first trimester.
BACKGROUND:LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance. METHODS: First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promoter reporter constructs was determined in BeWo trophoblast-like cells with luciferase assays. Adjusted odds ratio (OR) was calculated for the A/A genotype combined with maternal risk factors. RESULTS: The A/A, A/C, and C/C genotypes in the -98 promoter position were in Hardy-Weinberg equilibrium in the control but not in the PE group (p < 0.036). The dominant A/A genotype had higher frequency in the PE group (p < 0.001). The A/C and C/C genotypes protected from PE (p < 0.032). The ORs to develop term and all PE, calculated for the A/A genotype, previous PE, body mass index (BMI) >35, black ethnicity, and maternal age >40 were 15.6 and 11.0, respectively (p < 0.001). In luciferase assays, the "-98A" promoter variant had lower expression than the "-98C" variant in non-differentiated (-13%, p = 0.04) and differentiated (-26%, p < 0.001) BeWo cells. Forskolin-induced differentiation led to a larger expression increase in the "-98C" variant than in the "-98A" variant (4.55-fold vs. 3.85-fold, p < 0.001). CONCLUSION: Lower LGALS13 (PP13) expression with the "A" nucleotide in the -98 promoter region position (compared to "C") and high OR calculated for the A/A genotype in the -98A/C promoter region position, history of previous PE, BMI >35, advanced maternal age >40, and black ethnicity could serve to aid in PE prediction in the first trimester.
Authors: Y M Dennis Lo; K C Allen Chan; Hao Sun; Eric Z Chen; Peiyong Jiang; Fiona M F Lun; Yama W Zheng; Tak Y Leung; Tze K Lau; Charles R Cantor; Rossa W K Chiu Journal: Sci Transl Med Date: 2010-12-08 Impact factor: 17.956
Authors: N O'Gorman; D Wright; L C Poon; D L Rolnik; A Syngelaki; M de Alvarado; I F Carbone; V Dutemeyer; M Fiolna; A Frick; N Karagiotis; S Mastrodima; C de Paco Matallana; G Papaioannou; A Pazos; W Plasencia; K H Nicolaides Journal: Ultrasound Obstet Gynecol Date: 2017-06 Impact factor: 7.299
Authors: N Ardizzone; F Cappello; V Di Felice; F Rappa; F Minervini; S Marasà; L Marasà; W Rabl; G Zummo; C Sergi Journal: APMIS Date: 2007-11 Impact factor: 3.205
Authors: Nándor Gábor Than; Andrea Balogh; Roberto Romero; Eva Kárpáti; Offer Erez; András Szilágyi; Ilona Kovalszky; Marei Sammar; Sveinbjorn Gizurarson; János Matkó; Péter Závodszky; Zoltán Papp; Hamutal Meiri Journal: Front Immunol Date: 2014-08-20 Impact factor: 7.561
Authors: Andrea Balogh; Eszter Toth; Roberto Romero; Katalin Parej; Diana Csala; Nikolett L Szenasi; Istvan Hajdu; Kata Juhasz; Arpad F Kovacs; Hamutal Meiri; Petronella Hupuczi; Adi L Tarca; Sonia S Hassan; Offer Erez; Peter Zavodszky; Janos Matko; Zoltan Papp; Simona W Rossi; Sinuhe Hahn; Eva Pallinger; Nandor Gabor Than Journal: Front Immunol Date: 2019-06-19 Impact factor: 7.561